Contract Services
2021 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
EXECUTIVE INTERVIEW – Yourway: Supporting COVID-19 Studies & Vaccine Distribution
Leandro Moreira, Senior Vice President, Marketing and Business Development, Yourway, discusses what role the company will play in globally transporting COVID-19 vaccine(s), how Yourway is gearing up for this project, and the challenges of this extraordinary task.
ASSAY DEVELOPMENT – Case Study: How Custom Assay Development Helped Spur Precision Medicine Research in Multiple Myeloma
Steven Gross, MS, provides a behind-the-scenes look at the CMMC assay development process (from 2010 through today) to show how pharmaceutical companies can effectively partner with a laboratory to design customized assays that complement their drug discovery and development programs.
CDMO CASE STUDY – AJILITY: Streamlining Drug Product Manufacturing
Dustin Campbell says the AJILITY platform takes the burden off clients and allows his company to drive, manage, and support their drug product manufacturing, maximizing speed and success, while prioritizing these programs are driven to completion.
DEVICE DEVELOPMENT – Designing Devices for Inhaled Drugs
Andreas Meliniotis explains how there is plenty of opportunity for the development of new, improved devices to ensure inhaled drugs can be accessible for a wide range of patients and can treat various diseases and conditions effectively.
OVER-ENCAPSULATION CAPSULES – Double-Blind, Zero Bias: Over-Encapsulation — The Right Tool for Blinding Studies?
Julien Lamps believes that while many blinding options are available to drug sponsors and external clinical research partners, over-encapsulation remains a popular choice for its dosing simplicity, trial efficacy, patient accessibility, and cost-effectiveness.
OSD FORMULATIONS – Dissolving Bioavailability & Solubility Challenges in Formulation & Development
Vinod Patil, PhD, says many of the innovative and novel formulations introduced throughout the past decade have had to cope with poorly water-soluble APIs. Considering the pace of development, overcoming solubility issues will remain problematic, and this is especially true for important new classes of pharmaceuticals entering the market.
IMMUNOGENICITY TESTING – Regulatory Updates for Immunogenicity Assessment of Therapeutic Proteins
Leon Shi, PhD, Lan Li, MS, and Jing Shi, PhD, provide a high-level analysis of the significant changes to the guidance compared to the immunogenicity draft guidance released in 2016, and the implications for drug development programs.
SPECIAL FEATURE – Injection Devices: Will COVID-19 Deliver Growth to the Market?
Contributor Cindy H. Dubin interviews several leading companies and highlights trends in autoinjectors, pen injectors, wearable devices and connectivity, and prefilled syringes.
DRUG DEVELOPMENT – Bringing New Drugs to Patients Faster by Integrating Traditionally Separate Pharma Development Functions
Nutan Gangrade, PhD, says reducing R&D project timelines saves on overhead in development while increasing the likelihood of primacy in the marketplace (which engenders significantly more sales) and describes new approaches drug developers are taking to streamline drug development.
EXCLUSIVE ONLINE CONTENT
Excellence in Production: A Critical Contribution to the Pharmaceutical Industry
When it comes to the production of high-quality pharmaceuticals, excellence is the name of the game – in all production areas. It is the overarching goal of a well-defined course of action for….
WEBINAR ALERT! – Beyond Elemental Impurities: New Applications of ICP-MS
During this educational event, scientific experts will discuss several newer applications of ICP-MS in the pharmaceutical industry that capitalize on the technique’s versatility beyond the scope of elemental impurities.
Vectura Signs Development Agreement With Kinaset Therapeutics
Vectura Group plc recently announced it has signed a global outlicense and development agreement with Kinaset Therapeutics Inc. for the development and commercialization of….
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity
BD (Becton, Dickinson and Company), a leading global medical technology company, recently announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity….
Lonza Expands Development & Manufacturing Capabilities
Lonza recently announced a significant investment to expand its particle engineering and drug product capabilities to meet increased market demand at its Bend, OR, site…..